Applications include primary staging of high and intermediate unfavorable risk prostate tumors; determination of the optimal site for prostate biopsy and radiotherapy (RT) planning; identifying the site(s) of biochemical recurrence; assessment of response to treatment; and selection for PSMA theranostic treatment [85]. This evidence concerns the gene FOLH1 and prostate neoplasm.